← back to search

Carlos Gil Ferreira

BioClinica (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, RNA modifications and cancer, and Cancer Genomics and Diagnostics.
h-index
42
citations
10,608
works
372
NIH funding
primary concept
Medicine
email

Recent publications

Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling.
2026cited by 0position: contributordoi
Increased detection of NRG1 fusions in non-squamous non–small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort
Lung Cancer 2026cited by 0position: contributordoi
Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer
The Oncologist 2025cited by 10position: middledoi
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial
Lung Cancer 2025cited by 7position: middledoi
Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil.
2024cited by 2position: contributordoi
Later lines of systemic therapy in patients with metastatic colorectal cancer: real-world data from a setting with barriers to access cancer therapies.
2024cited by 2position: contributordoi
Preventive and therapeutic assessment program for mucositis in patients with cancer: promising advances in stomatological care
Brazilian Journal of Oncology 2024cited by 0position: contributordoi
Unveiling the Landscape of Brazilian Clinical Oncologists: Challenges, Diversity, and Quality Care
Brazilian Journal of Oncology 2024cited by 0position: contributordoi
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet 2023cited by 547position: middledoi
Intracranial efficacy of sotorasib versus docetaxel in pretreated<i> KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).
Journal of Clinical Oncology 2023cited by 27position: middledoi
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
2023cited by 3position: contributordoi
Challenges and opportunities in building a health economic framework for personalized medicine in oncology.
2023cited by 1position: contributordoi
Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective.
2023cited by 1position: contributordoi
Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario.
2022cited by 3position: contributordoi
Real-World Evidence of Health Outcomes Related to Lung Stereotactic Body Radiation Therapy in Brazil.
2022cited by 1position: contributordoi
Fotobiomodulação na prevenção e tratamento da mucosite oral: relato de caso
Research, Society and Development 2022cited by 1position: contributordoi
Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients.
2021cited by 7position: contributordoi
Demographic and Clinical Outcomes of Brazilian Patients With Stage III or IV Non-Small-Cell Lung Cancer: Real-World Evidence Study on the Basis of Deterministic Linkage Approach.
2021cited by 7position: contributordoi
Cyclic ACTH-secreting thymic carcinoid: a case report and review of the literature.
2021cited by 3position: contributordoi
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology 2020cited by 441position: middledoi
Tumor-node-metastasis staging and treatment patterns of 73,167 patients with lung cancer in Brazil.
2020cited by 12position: contributordoi
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet 2019cited by 3,303position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 14 papers (2020–2026) · 5 papers (2022–2026)Rodrigo Dienstmann · MedSIR (Spain)5 papers (2022–2026) · 3 papers (2023–2024)Enriqueta Felip · Université Grenoble Alpes2 papers (2023–2025)Konstantinos Syrigos · Yale Cancer Center2 papers (2023–2025) · 2 papers (2023–2025)Paulo Salles · Faculdade de Ciências Médicas de Minas Gerais2 papers (2022–2023) · 2 papers (2022–2023)Clarissa Baldotto · D’Or Institute for Research and Education2 papers (2022–2023)Tatiane Montella · Centro de Excelência em Bioinformática2 papers (2023–2024)Pedro Nazareth Aguiar Junior · Sociedade Brasileira de Oncologia Clínica2 papers (2023–2023)Veronica Aran · Universidade Federal do Rio de Janeiro2 papers (2021–2022)Kadoaki Ohashi · Hebron University2 papers (2023–2025)Anne‐Marie C. Dingemans · Erasmus University Rotterdam2 papers (2023–2025)Normand Blais · HEC Montréal2 papers (2023–2025)Colin R. Lindsay · Cancer Research UK2 papers (2023–2025)Cynthia Obiozor · University of Kansas2 papers (2023–2025)Lorenzo Livi · Istituti di Ricovero e Cura a Carattere Scientifico2 papers (2023–2025)Sang‐We Kim · Harbin Medical University2 papers (2023–2025)